Essay

The time for change is now

Chris Pickett
Sept. 3, 2020

The U.S. biomedical research enterprise is riddled with systemic flaws that slow the progress of research. These flaws, and the disproportionate strain they put on different parts of the research workforce, have been put into stark relief during the COVID-19 pandemic. While it is understandable that most researchers want to find a way to return to some semblance of normal before considering reforms, that thinking is wrong.

No-UTurn-445x445.jpg

The time for reform is now. Right now.

Returning to the status quo — ramping up research programs without significant policy changes — is an attempt to return to a system that worked for the privileged few. Now is the time to think critically about reforming departmental culture and enacting real, long-lasting reforms to make the research enterprise more just and equitable.

COVID-19 provides a window to consider reforms, and the research stoppage provides the space and time to implement them. Universities and departments should consider implementing long-term solutions to long-standing problems.

In late April, I convened a discussion series to delve into the systemic issues in biomedical research and how those issues were amplified by the pandemic. During four sessions, the 11 speakers talked about the challenge of trying to keep a research career going at a distance while caring for family members. Concerns about research evaluation, funding and career progression all figured prominently in their remarks. Just as prominent were concerns that departments and universities would fail to recognize and respect the disproportionate effects COVID-19 is having on the careers of women and people from underrepresented backgrounds.

From these discussions, I drafted a white paper listing 17 recommendations universities and departments should consider to enact long-term change.

For example, more than 300 universities have paused tenure clocks due to COVID-19. Rather than stop with this short-term change, they should take this opportunity to revise how they evaluate a researcher’s contributions to the university community, irrespective of the pandemic.

Similarly, departments should revise graduate admissions standards in a way that is broadly inclusive and applicable once the pandemic is behind us.

In the wake of the recent Black Lives Matter protests, universities made clear commitments to make their campuses more equitable and inclusive. These commitments are similar to previous performative commitments to equity and inclusion.

Only through intentional hiring, retention and promotion of BIPOC (Black, indigenous and people of color) scholars can universities actually live up to their commitments.

Departments should work immediately on how search committees will implement established protocols to prioritize hiring BIPOC postdocs into faculty positions once hiring freezes are lifted, and how they will revamp retention and promotion policies to value the typically underappreciated community service done by these faculty members.

Additionally, the pandemic and the Trump administration have pushed the scientific community to vocally defend foreign-born researchers working in the U.S. However, universities and departments could make real, beneficial reforms to demonstrate their commitment to nearly 50% of the biomedical trainee workforce by equalizing the pay of trainees regardless of national origin and enact policies that prevent faculty members from threatening a trainee’s visa status to extort labor.

These recommendations are forward-looking, and most are intended to make long-term positive changes. If the pandemic has convinced universities and departments to make accommodations for their current crop of trainees and faculty, then they have the space to make permanent changes as well.

The biomedical research enterprise was not perfect before COVID-19, but we have a chance to install a better system for all members of the biomedical research enterprise for years to come.

The opportunity is here. The time is now.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Chris Pickett

Chris Pickett is a porfolio analyst at Lexical Intelligence. He served as director of Rescuing Biomedical Research and founder and executive director of Indivisible Montgomery. He is a former ASBMB policy fellow.

Related articles

Gary Felsenfeld (1929–2024)
Michael M. Gottesman, Christopher Wanjek & Martin Gellert
Upcoming opportunities
ASBMB Today Staff

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Opinions

Opinions highlights or most popular articles

'I can do it without making a face'
Essay

'I can do it without making a face'

July 10, 2024

Betty B. Tong describes the life lessons she learned 35 years ago as a Chinese graduate student in the U.S.

Why AlphaFold 3 needs to be open source
Essay

Why AlphaFold 3 needs to be open source

July 7, 2024

The powerful AI-driven software from DeepMind was released without making its code openly available to scientists.

Summertime can be germy
Advice

Summertime can be germy

July 6, 2024

A microbiologist explains how to avoid getting sick at the barbecue, in the pool or on the trail.

Shades of cultural difference
Essay

Shades of cultural difference

July 4, 2024

“I was perplexed,” Humphrey Omeoga writes. “(M)y greetings frequently went unacknowledged. In Nigeria, people are always willing to accept and return greetings, especially from a foreigner.”

A primer to starting grad school
Advice

A primer to starting grad school

June 28, 2024

No matter what program you've chosen, the first few weeks can be challenging. Here are a few tips for smoother sailing in your first month.

Advancing science through adventure
Essay

Advancing science through adventure

June 27, 2024

“Everyone around me assumed that the privilege and support of my family, coupled with my natural proclivity for science and writing, would lead me inevitably to biomedical science,” Yamini Dalal writes. “And so it has.”